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TACROLIMUS is safe and effective for primary renal 
. transplantation,l but perhaps even more striking is the 
utility of this drug as a salvage agent for refractory renal 
allograft rejection.2 We previously reported that graft sal-
vage with tacrolimus conversion was achieved in 74% (57 of 
77) of patients with refractory acute rejection on baseline 
cyclosporine (CyA) therapy.2 Since then, we have entered 
an additional 92 patients for a total of 169 renal transplant 
recipients who have been converted to tacrolimus. 
MATERIALS AND METHODS 
Between July 14, 1989 and May 24, 1994, 169 patients (98 male, 71 
female; 132 cadaveric donors, 37 living donors) with a mean age of 
36.2 ± 13.1 years with ongoing allograft rejection under baseline 
CyA immunosuppression were converted to tacrolimus. One hun-
dred thirty-eight patients (82%) were primary transplant recipients 
and 31 (18%) had been retransplanted. Maintenance immunosup-
pression had consisted of CyA and prednisone in all patients, either 
with (n = 117,69%) or without (n = 52,31%) azathioprine (AZA). 
All patients had previous antirejection therapy (high-dose cortico-
steroids) and 144 of 169 patients (85%) had also received at least 
one course of an antilymphocyte preparation. Acute cellular rejec-
tion (ACR) was present on biopsy in all 169 patients prior to 
conversion. Tacr9limus was started at 0.2 to 0.3 mg/kgld in divided 
doses every 12 hours starting 12 to 24 hours after the last CyA dose. 
Data were analyzed for significance by two-tailed Student's t test or 
chi-square analysis when appropriate. 
RESULTS 
With a mean follow-up of 30.0 ± 2.4 months, 159 of 169 
patients (94%) are alive and 125 of 169 patients (74%) have 
achieved graft salvage. A total of 28 of 169 patients (17%) 
were dialysis dependent at the time of tacrolimus conver-
sion. Thirteen of these (46%) currently have functioning 
grafts with a mean serum creatinine (sCr) of 2.15 ± 0.37 
mgldL at a mean follow-up of 37.3 ± 16 months. Excluding 
these 13 patients, the overall mean sCr in the remaining 112 
patients with preconversion graft function improved from 
3.1 ± 1.7 mg/dL to 2.3 ± 1.1 mgldL postconversion (P = 
. 0002). The average preconversion prednisone dose of 
28.0 ± 9.0 mgld has been lowered to 6.6 ± 5.1 mg/d, and 28 
of 125 patients (22%) are on tacrolimus monotherapy. Of 
the 144 patients receiving preconversion antilymphocyte 
preparations (average length of treatment 14.2 ± 5.8 days). 
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117 (81%) were salvaged by tacrolimus conversion. There 
were 44 failures in the 169 patients (26%); 22 due· to 
ongoing renal allograft rejection and 22 due to repeat 
rejection episodes after initial successful rescue. 
DISCUSSION 
The profile of patients in this expanded study is very similar 
to that reported previously.2 The majority (144 of 169, 85%) 
of the patients had failed prior treatment with antilympho-
cyte preparations and a subset of 28/169 (17%) of the 
patients had rejections so severe as to necessitate ongoing 
dialysis therapy prior to conversion. Graft salvage was 
obtained in 125 of 169 patients (74%) with a 30-month 
follow-up, identical to the salvage rate we previously re-
ported but with a larger group of patients with longer 
follow-up.2 The previously reported ability to taper and 
even stop prednisone in approximately 20% of patients 
successfully salvaged was maintained in this expanded ex-
perience. In addition to the now well-established graft 
salvage effects of tacrolimus, several other agents have 
shown initial promise as rescue agents, including mycophe-
nolate mofetil, 15-deoxyspuergualin, and perhaps sirolimus. 
Whether these agents will provide long-lived salvage rates 
and afford the opportunity to wean steroids after rescue 
(such as is possible with tacrolimus) remains to be deter-
mined. We currently recommend that tacrolimus conver-
sion be considered an alternative to antilymphocyte prepara-
tions for steroid-resistant rejection in CyA-based regimens. 
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